Underrated Pharma Stocks: Merck, Novo Nordisk & Pfizer

Merck (MRK):: Faces patent exclusivity loss for Keytruda by 2028, but its forward price-to-earnings ratio of 9.4 is attractive compared to the healthcare sector average of 16.5. Developing a subcutaneous version of Keytruda could extend its patent life. Why this matters: Merck's dividend payouts have increased by 39.3% in the past five years, offering a forward yield of 4%, making it a solid dividend stock.

Novo Nordisk (NVO):: Shares have plummeted by more than 50% in the past year due to underwhelming trial results for its weight loss drug, CagriSema. However, it has a promising next-gen treatment, amycretin, and is expanding its popular weight loss drug, Wegovy, to new markets. Why this matters: Strong profit margins of 35% over the trailing 12 months and growth opportunities still ahead may make the stock a steal for long-term investors.

Pfizer (PFE):: Wall Street analysts see an upside potential of nearly 20%, but many investors are not on the same page. Faces challenges including pipeline setbacks and loss of patent exclusivity for drugs like Eliquis and Ibrance. Why this matters: An attractive dividend with a forward yield of 6.79% and a low valuation of roughly 8.7 times forward earnings make it a potentially undervalued stock.

Q: What challenges do Merck, Novo Nordisk, and Pfizer face?

Q: What are the potential upsides for these stocks?

Merck, Novo Nordisk, and Pfizer are potentially undervalued pharma stocks with long-term growth opportunities.

Investors should consider the challenges and upsides of each company before making investment decisions.

These stocks may offer a combination of growth and dividend income potential.